Olive Capital
Olive Capital is an investment syndicate based in Geneva, Switzerland, founded in 2019. The firm focuses on providing its members with access to early-stage investment opportunities in private, innovative companies, particularly in the web3 sector. By leveraging a robust network of entrepreneurs across Europe and the United States, Olive Capital has facilitated investments in notable companies such as Revolut, ActionDesk, 15Five, and Captiv8. The organization regularly identifies and presents new investment opportunities to its members, though it does not offer financial advice.
Meliora Therapeutics is a biotech startup focused on developing innovative cancer therapies through a machine learning-driven platform. The company aims to identify the true mechanisms of action of oncology medications by utilizing a proprietary prediction atlas that maps drug mechanisms. This approach allows Meliora to streamline the drug development process by reducing the time and costs typically associated with traditional methods. By pinpointing the specific actions of therapeutic molecules, Meliora Therapeutics seeks to enhance the efficacy of cancer treatments and accelerate the delivery of life-saving therapies to patients.
Orchid is a reproductive technology startup that specializes in detecting genetic disorders through advanced genomic analysis. Founded in 2019 and headquartered in San Francisco, California, Orchid offers a preconception system that evaluates both partners' genomes to identify predispositions to various common diseases, including heart disease, diabetes, and certain cancers. Utilizing an at-home saliva test, Orchid provides couples with a detailed "Couple Report" that assesses genetic risks and models the potential genetic combination of a future child. If elevated risks are identified, the company offers valuable insights to help couples manage these risks, which may include monitoring biomarkers or considering options like in vitro fertilization. Orchid's results are developed in collaboration with leading experts in reproductive medicine and genetics, ensuring accuracy and reliability for its clients.
Orchid is a reproductive technology startup that specializes in detecting genetic disorders through advanced genomic analysis. Founded in 2019 and headquartered in San Francisco, California, Orchid offers a preconception system that evaluates both partners' genomes to identify predispositions to various common diseases, including heart disease, diabetes, and certain cancers. Utilizing an at-home saliva test, Orchid provides couples with a detailed "Couple Report" that assesses genetic risks and models the potential genetic combination of a future child. If elevated risks are identified, the company offers valuable insights to help couples manage these risks, which may include monitoring biomarkers or considering options like in vitro fertilization. Orchid's results are developed in collaboration with leading experts in reproductive medicine and genetics, ensuring accuracy and reliability for its clients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.